Cancers related to obesity are on the rise, especially among millennials; a right-to-try advocate is receiving treatment for his amyotrophic lateral sclerosis under the new law; and women's brains age more slowly than men's.
The risk of developing obesity-related cancer is on the rise, especially among young adults. A study published in Lancet Public Health found that for 6 of the 12 obesity-related cancers—multiple myeloma, colorectal, uterine, gallbladder, kidney, and pancreatic—the risk of disease increased among those aged 25 to 49, with risk increases more prevalent among those younger. While incidence, with the exception of colorectal cancer, also jumped for older adults, the increases were smaller.
A prominent right-to-try advocate has confirmed that he is receiving access to an experimental treatment for his amyotrophic lateral sclerosis under the right-to-try law, reported STAT News. Matt Bellina is the second patient to receive treatment under the law that was approved in May 2018. The treatment comes from BrainStorm, which is currently running a phase 3 trial for a stem cell treatment for the disease.Women’s brains tend to age more slowly than men’s, according to a study published in Proceedings of the National Academy of Sciences. The study found that while age reduces the metabolism of all brains, women’s brains remain more youthful throughout their lifespan, suggesting that sex differences during brain development have implications for subsequent trajectories of brain aging.
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
Obesity at Cancer Diagnosis Linked to Worse Survival Outcomes in Pediatric Patients
January 13th 2025Pediatric patients considered obese at cancer diagnosis are linked to significantly worse survival outcomes, especially those with acute lymphoblastic leukemia and central nervous system tumors.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
FDA Approves Tislelizumab-jsgr as First-Line Therapy for HER2– Gastric Cancers
January 2nd 2025Tislelizumab-jsgr (Tevimbra) was approved in combination with chemotherapy for the treatment of unresectable or metastatic HER2-negative (HER–) gastric or gastroesophageal junction adenocarcinoma (G/GEJ) in adults whose tumors express PD-L1.
Read More